To eliminate apicomplexan parasites, inhibitory compounds must cross host cell, parasitophorous vacuole, and parasite membranes and cyst walls, making delivery challenging. Here, we show that short oligomers of arginine enter Toxoplasma gondii tachyzoites and encysted bradyzoites. Triclosan, which inhibits enoyl-ACP reductase (ENR), conjugated to arginine oligomers enters extracellular tachyzoites, host cells, tachyzoites inside parasitophorous vacuoles within host cells, extracellular bradyzoites, and bradyzoites within cysts. We identify, clone, and sequence T. gondii enr and produce and characterize enzymatically active, recombinant ENR. This enzyme has the requisite amino acids to bind triclosan. Triclosan released after conjugation to octaarginine via a readily hydrolyzable ester linkage inhibits ENR activity, tachyzoites in vitro, and tachyzoites in mice. Delivery of an inhibitor to a microorganism via conjugation to octaarginine provides an approach to transporting antimicrobials and other small molecules to sequestered parasites, a model system to characterize transport across multiple membrane barriers and structures, a widely applicable paradigm for treatment of active and encysted apicomplexan and other infections, and a generic proof of principle for a mechanism of medicine delivery.
T he vast majority of interesting small molecules will never be used for therapeutics because they cannot traverse biologic barriers to reach their targets. A special challenge for the development of antimicrobials effective against apicomplexan parasites is delivery. Effective agents have to gain entry to host cells, cross the parasitophorous vacuole, and enter parasites and their specialized organelles. This is potentially more difficult with Toxoplasma gondii bradyzoites, which reside in cysts composed partly of host and partly of parasite constituents. The studies described herein were performed to determine whether short oligomers of arginine (Fig. 1A) could provide a solution to these challenges. Arginine oligomers linked to immunomodulatory and antitumor compounds can actively transport such compounds across a variety of epithelial barriers, including skin, lung, and eye (1) (2) (3) (4) . Oligoarginine-medicine conjugates have been administered safely to experimental animals and humans (ref. 1 and unpublished data).
Better approaches for treating apicomplexan parasite infections (e.g., toxoplasmosis and malaria) are needed. For example, T. gondii bradyzoites infect 30-50% of people throughout the world, but no currently used medicines eradicate this slowly growing, encysted, latent parasite that causes chronic, lifelong infections in brain and eye with recrudescence causing severe illness (5) . Available antimicrobial agents to eliminate rapidly growing T. gondii tachyzoites, which cause tissue destruction during active infection, are limited by toxicity and allergy (5) .
Enoyl-ACP reductase (ENR) is a key enzyme active in fatty acid synthesis (6) . Bacterial and apicomplexan fatty acid synthesis occurs by the type II pathway (6) (7) (8) (9) (10) (Fig. 5 , which is published as supporting information on the PNAS web site) and depends on monofunctional polypeptides, including ENR. In contrast, mammalian fatty acid synthesis occurs by the type I pathway in which the key enzymes are present on a polyfunctional single polypeptide (6) (7) (8) (9) (10) . In apicomplexans, type II fatty acid synthesis enzymes are in a plastid organelle (6, 8) .
Some monofunctional type II enzymes had been identified in Plasmodia and T. gondii (6) (7) (8) (9) (10) , but T. gondii ENR (TgENR) had not been identified. The antimicrobial agent 5-chloro-2-[2,4-dichlorophenoxy]phenol (triclosan) had been found to inhibit bacterial ENRs (11) . We (6) and Surolia and Surolia (9) had found that M concentrations of triclosan dissolved in DMSO inhibit replication of apicomplexan parasites, presumably by binding to, and inhibiting, apicomplexan ENR. Triclosan was active only when solubilized in DMSO (6, 9) . Structures of triclosan, oligomers, and conjugates of oligoarginines are shown in Fig. 1 (see also Fig. 5 ).
Materials and Methods
Short Arginine Oligomers, Conjugates, and Controls. Peptides were synthesized by using solid-phase techniques and commercially available fluorenylmethoxycarbonyl amino acids, resins, and reagents with an Applied Biosystems 433 peptide synthesizer. Fastmoc cycles were used with O-(7-azabenzotriazol-1-yl)-1,1,3,3-tetramethyluronium hexaf luorophosphate (HATU). Peptides and conjugates were cleaved from resin by using 95% trifluoroacetic acid and 5% triisopropylsilane for 24 h. Peptides were subsequently filtered from resin, precipitated with diethyl ether, purified by using HPLC reverse-phase columns, and characterized by using 1 H NMR and electrospray MS.
For synthesis of triclosan-Orn(FITC)-Arg n -CONH 2 , 4 and 5, triclosan was reacted with ␣-bromoacetic acid to provide the desired ␣-substituted acetic acid product. Attachment of the resin-bound carrier was accomplished by reaction of this acetic acid product with the appropriate oligomer of L-arginine(2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl, Pbf) containing an N-terminal L-ornithine(methyltrityl). After cleavage of the side-chain methyltrityl protecting group with 1% trifluoroacetic acid in dichloromethane, the conjugates were labeled with FITC in the presence of diisopropylethylamine (DIPEA). The conjugates were then deprotected and cleaved from the resin by using the previously described protocol. For the synthesis of triclosan-Orn(tetramethylrhodamine isothiocyanate)-Arg 8 -CONH 2 , ent-6, tetramethylrhodamine isothiocyanate was reacted in the solution phase with triclosan-D-Orn-DArg 8 -CONH 2 in the presence of DIPEA. Triclosan was reacted with glutaric anhydride (GA) in the presence of DIPEA to provide the desired glutaric acid product, i.e., triclosan-GAArg n -CONH 2, 7 and 8. Attachment of the carrier was accomplished by the solution-phase reaction with the appropriate oligomer of D-or L-arginine. For the synthesis of triclosan-acetic Abbreviations: ENR, enoyl-ACP reductase; TgENR, Toxoplasma gondii ENR; Pbf, 2,2,4,6,7-pentamethyldihydrobenzofuran-5-sulfonyl.
acid-Arg 8 -CONH 2 , 9, the previously described ␣-substituted acetic acid product was attached to the carrier by reaction with the resin-bound octa-L-arginine(Pbf). The conjugate was subsequently cleaved from the resin, and the Pbf sulfonamides were removed. For the synthesis of GA-Arg n -CONH 2 , 10 and 11, the resin-bound oligomer of L-arginine(Pbf) was reacted with GA in the presence of DIPEA, followed by cleavage of the resin and Pbf deprotection.
The half-life of conjugate 7 decomposition in PBS was determined by using HPLC to monitor the change in the ratio of conjugate-to-internal standards (benzoic acid) over time.
T. gondii Parasites. Tachyzoites of the RH strain were maintained and used in experiments as described (12, 13) . GFP-, plastidlabeled RH strain parasites were kindly provided by B. Streipen and D. Roos (University of Pennsylvania, Philadelphia). Production and isolation of T. gondii cysts were as described (14) .
Studies on the Uptake of Short Arginine and Lysine Oligomers into T.
gondii. Live cells incubated with conjugates were examined by using a Zeiss Axiovert inverted fluorescence microscope or Zeiss Axioplan equipped with cooled charge-coupled device camera. For flow cytometry, parasites and cells were incubated in PBS͞2% FCS containing 12.5 M of each oligomer at 18°C for 10 min, washed in cold PBS three times, resuspended in PBS, and then analyzed by flow cytometry with a FACScan and CELL QUEST software. Before analysis, intracellular parasites were exposed to 12.5 M conjugate for 10 or 30 min.
Treatment with Azide. Parasites were preincubated for 30 min with 0.5% azide (tachyzoites, bradyzoites) or 0.5-2% azide (cysts), all in 2% FCS͞PBS buffer, before the addition of 12.5 M conjugate.
Cloning and Sequencing of TgENR. A cDNA library was screened to identify and characterize the TgENR gene as described (15, 16 ) (see Supporting Text, which is published as supporting information on the PNAS web site).
Expression and Purification of Recombinant TgENR.
A construct of TgENR containing residues 103-417 (and lacking the putative signal and transit peptides) was designed for in vivo cleavage by tobacco etch virus (TEV) protease. Amplified DNA encoding residues 103-417 of TgENR was ligated into a modified version of the pMALc2x vector (pMALcHT) in which the linker region was altered to contain nucleotides encoding a TEV protease cleavage site followed by a six-histidine tag (17) . The resulting ligation product, pSTP8, was transformed into BL21 Star (DE3) cells (Invitrogen). These cells were cotransformed with the pRIL plasmid from BL21-CodonPlus (DE3) cells (Stratagene) and a plasmid (pKM586) encoding the TEV protease (18) . Cells were grown, harvested, and lysed as described (17) . TgENR was purified by using metal chelate and anion exchange chromatography (see Fig. 3B ).
Effect of r8-Triclosan on Recombinant TgENR. The activity of TgENR was assayed by using crotonyl-CoA as a substrate and monitoring the consumption of the NADH cofactor. Inhibition by r8-triclosan over a 24-h period was measured by incubating TgENR at 37°C with different concentrations of r8-triclosan. Aliquots were removed at 0, 12, and 24 h and assayed for TgENR activity. Briefly, 10 l of 1 mM NADH and 10 l of 1 mM crotonyl-CoA were added to 80 l of incubated TgENR͞r8-triclosan, and the reaction was followed for 120 s in a Beckman DU-640 spectrophotometer. Final concentration of TgENR was 11.6 nM, and the final concentrations of r8-triclosan were 2 M, 0.4 M, 80 nM, 16 nM, 3.2 nM, 640 pM, and 128 pM. TgENR was inhibited by r8-triclosan with an IC 50 value Ͼ1 M at 0 h, an IC 50 value ϭ 40 nM Ϯ 10 nM at 12 h, and an IC 50 value Ͻ16 nM at 24 h (see Fig. 3C ). The IC 50 value at 24 h is an upper limit because inhibition cannot be properly measured near the concentration of TgENR used in these assays (11.6 nM).
Assays to Assess Inhibition of T. gondii Tachyzoite Growth and Effect of Antimicrobial Agents on Host Cells in Vitro.
These studies were performed as described (12, 13) .
Effect of r8-Triclosan on Tachyzoites in Vivo.
One thousand RH strain parasites were inoculated i.p. into five female SW mice (each Ϸ25 g and between 2 and 4 months of age). Lypholized releasable r8-triclosan or triclosan were resuspended in Dulbecco's PBS. Forty milligrams per kilogram of r8-triclosan or control PBS was inoculated i.p. each day. On the fourth day, 1.5 ml of PBS (pH 7.4) was inoculated. All available peritoneal fluid plus PBS was withdrawn on the fourth day. Total numbers of parasites and concentrations of parasites were quantitated microscopically. 
Results and Discussion
Initially, uptake of fluoresceinated hepta-D-arginine (r7, compound 1, Fig. 1 A) and control compounds penta-D-arginine (r5, compound 2, Fig. 1 A) and hepta-L-lysine (K7, compound 3, Fig.  1 A) into extracellular and intracellular tachyzoites, and extracellular and encysted bradyzoites, was studied by using deconvolution fluorescence microscopy and flow cytometry ( Fig. 1  B-F) . R designates levo isomer, r designates dextro isomer, and the number after r indicates the number of arginines in the compound. Short arginine oligomers were found to cross all membranes and to enter each life cycle stage and compartment ( Fig. 1 B-F) . Deconvolution fluorescence microscopy revealed that r7 facilitated uptake of fluoresceinated compounds into tachyzoites (Fig. 1B Inset) . Flow cytometric analysis (Fig. 1B) demonstrated that uptake of r7 was greater than that of r5 or K7 (seven arginines Ͼ Ͼ five arginines or seven lysines). This finding was consistent with earlier studies demonstrating that longer oligomers of arginines (seven or eight) entered certain eukaryotic cells better than shorter oligomers (one to four). Deconvolution microscopy demonstrated that short arginine oligomers could cross cyst walls and enter encysted bradyzoites ( Fig. 1C and Movie 1, which is published as supporting information on the PNAS web site). Uptake of short arginine oligomers into tachyzoites and bradyzoites was very rapid (seconds), and in bradyzoites, the fluoresceinated compound moved from the cytoplasm to the nucleus over the first day (data not shown).
Floresceinated, nonreleasable triclosan R8, conjugate 4, then was studied by microscopic analyses. The conjugated triclosan was taken up by extracellular tachyzoites and bradyzoites within cysts Ϸ10 s after addition (Fig. 1 D-F) . Treatment with azide blocked uptake of short arginine oligomers linked to triclosan by tachyzoites (Fig. 1D) and bradyzoites (Fig. 1E ) but did not completely inhibit uptake into encysted bradyzoites under the conditions studied (Fig. 1F) . Thus, uptake into tachyzoites and bradyzoites is a facilitated process. Uptake of fluoresceinated triclosan R8 (conjugate 4) into tachyzoites was substantially greater (one and a half logs) than triclosan R4 (conjugate 5), after incubation for 10 s, 1 min, and 10 min. Uptake of triclosan R8 increased over time (data not shown). As uptake into isolated bradyzoites was blocked by azide, the inability of azide to completely abrogate uptake by encysted bradyzoites is surprising and suggested that more than a single mechanism of uptake might be involved in uptake across the cyst wall.
Fluorescein-tagged conjugate 4 and its enantiomer both entered host fibroblasts. T. gondii is an obligate intracellular parasite and resides inside a specialized vacuolar compartment known as the parasitophorous vacuole delimited by the parasitophorous vacuole membrane. To determine whether the carrier conjugated to triclosan can enter this specialized compartment, tachyzoites within a vacuole in human fibroblasts were studied. Intracellular tachyzoites took up fluoresceinated r8-triclosan (conjugate ent-4) within minutes ( Fig. 2A) . This finding was also confirmed by flow cytometric analysis (Fig. 2B) .
Previously, the only apicomplexan ENR identified was that of Plasmodium falciparum. We (17) and others (19) have cloned, sequenced, and solved the structure of P. falciparum ENR. It was of interest to compare P. falciparum ENR and TgENR for the present study, particularly with reference to their triclosan binding sites. Portions of TgENR were identified in a database, full-length cDNA clones were isolated and sequenced, deduced amino acid sequences were determined, and enzymatically active recombinant protein was produced (Fig. 3) . Analysis of the deduced amino acid sequence revealed that key amino acid residues are conserved between T. gondii (Fig. 3A , GenBank accession no. AY372520), P. falciparum, Brassica napus, and bacterial ENRs and that 11 amino acid residues involved in triclosan binding are also conserved (Fig. 3A) . This result suggests that triclosan is likely to have a similar mode of inhibition in T. gondii as in other species. In keeping with a plastid localization of this enzyme in other apicomplexans, a bi-partite transit sequence consisting of a cleavable von Heijne secretory signal (the first 27 aa) followed by a chloroplast-like targeting sequence (amino acid numbers 28-66) were identified. Alignment with the genomic DNA sequence in the database indicated that there are four introns. In analyzing the amino acid sequence of P. falciparum ENR, several amino acid insertions were found. B. napus ENR had inserts corresponding to two of those from P. falciparum ENR. The sequence of TgENR has multiple amino acid sequences that coincide with those inserts Parasite nuclei (arrows) and host cell nuclei (HN) were stained with Hoechst. FITC signal is seen in host cell cytoplasm (HC) and nuclei (HN), and in parasites residing in parasitophorous vacuole (v). (Scale bar ϭ 10 m.) (B) Uptake of triclosan r8 conjugate (nonreleasable conjugate 4) by extracellular and intracellular tachyzoites. Flow cytometric analysis showing representative dot blots of RH strain (pink) and transgenic parasites expressing the GFP (ACP-GFP, extracellular, red; intracellular, green) exposed to r8-triclosan conjugated to rhodamine (ent-6) for 10 min. Intracellular parasites were exposed to the carrier and then released from the host cells before analyses. present in both P. falciparum and B. napus ENRs. P. falciparum ENR also contained a third polar insert that had no counterpart in other species. Analysis of the TgENR sequence indicates only partial conservation of this larger malarial insert. The function(s) and origins of these inserts are unknown.
The predicted ENR structure suggested a strategy whereby octaarginine could be conjugated to triclosan both in a releasable manner, exposing a key part of the inhibitor essential in the binding of triclosan to ENR only upon its release, and in a nonreleasable manner, preventing access to the critical site where a hydroxyl in triclosan binds apicomplexan ENR (Figs. 1  and 5 ). Triclosan's insolubility in aqueous media, unless prepared with DMSO or ethanol, limits its clinical use, but provided us with an opportunity to compare efficacy against T. gondii of triclosan alone and triclosan delivered by conjugation to octaarginine.
We then studied effects of triclosan conjugated to short oligomers of arginine on activity of recombinant ENR (Fig. 3 B  and C) and on intracellular T. gondii (Fig. 4 A and B) . For these studies, a releasable conjugate of triclosan, compound 7, was synthesized. Attachment of triclosan to octaarginine was achieved by readily hydrolyzable ester bonds so that the triclosan cargo could be released to bind to TgENR and thus to inhibit the parasite.
Inhibition of enzyme activity paralleled kinetics of release of the conjugated triclosan (Fig. 3) . Releasable triclosan octaarginine (conjugates 7 and 8) were effective in inhibiting T. gondii tachyzoites (Fig. 4) , as was triclosan but only when dissolved in DMSO (data not shown). Neither nonreleasable triclosan R8 (conjugate 9) nor octaarginine alone was active, indicating the specificity of triclosan (Fig. 4) .
As the nonreleasable triclosan R8 (conjugate 9) was without effect, triclosan must be released from R8 to be active (Fig. 1) . It is not sufficient just to make triclosan soluble, and R8 (compound 10) and R4 (compound 11) had no effect on T. gondii alone.
A kinetic analysis of the pharmacologic effect of the conjugate (T 1/2 ϭ 12 h) revealed that some activity could be detected after short exposure: For example, after a brief (10 min to 2 h) exposure there was a modest effect of r8-triclosan (conjugate ent-7) in PBS, but not triclosan in PBS, when uptake of [ 3 H]uracil by Toxoplasma tachyzoites was measured in the last 18 h of 3.5 days of culture (data not shown). Two hours was substantially less than the time required for 50% dissociation of r8-triclosan (conjugate ent-7) (half-life of dissociation in PBS ϭ 12 h).
Exposure throughout the first 48 h was essential, however, for full efficacy (i.e., IC 90 ) of r8-triclosan (compound ent-7) in medium and serum (Fig. 4B) . This finding is consonant with the ''delayed death phenotype'' seen for antimicrobial agents, such as clindamycin and azithromycin, believed to effect plastidassociated processes.
To be active against the parasite, triclosan must be targeted to, and released in the vicinity of, or within, the plastid where enzymes of apicomplexan fatty acid synthesis are targeted and active (6) (7) (8) (9) (10) . Because short oligomers of arginine alone and linked to triclosan rapidly entered the parasite cytoplasm and nucleus, we wanted to determine whether short oligomers of arginine linked to triclosan also were in close proximity to or entered the plastid, as the delayed death phenotype of triclosan suggested that they were likely to act on a plastid associated process. Also, analysis of TgENR suggested that the plastid was a likely site of action of this inhibitor of ENR. To determine For the PBS-exposed cultures (not controls), T or Tr8 PBS then were replaced at varying intervals with Iscove's modified Dulbecco's medium-FCS, which was present for the remainder of the 3.5-day culture period. Parasite growth also was determined by [ 3 H]uracil uptake at the end of 3.5 days of culture in growth medium (data not shown). Brief exposures to Tr8 partially inhibited parasite growth and the 3.5-day exposure (or a 48-h exposure, data not shown) inhibited parasite growth almost completely. Unconjugated triclosan had no effect. The photomicrographs (Giemsa stain) on the right show the ''protective'' effect of Tr8, but not T, in PBS on the infected host cell monolayer. The large empty areas represent host cell destruction by intracellular parasite growth, which is inhibited by r8-conjugated triclosan and not by the triclosan in PBS. (C) Subcellular distribution of r8-triclosan conjugate in tachyzoites was determined by deconvolution microscopy using nonreleasable r8-triclosan conjugated to rhodamine, and transgenic parasites expressing the GFP targeted to the parasite plastid organelle. whether short oligomers of arginine delivered triclosan to the vicinity of the plastid, a rhodamine-conjugated r8 linked to triclosan (ent-6) was synthesized to facilitate colocalization studies of r8 conjugate, and a parasite in which the plastid was labeled with GFP was examined. These studies showed a dense ring of rhodamine signal at the perimeter of the plastid that colocalized with the outer portion of the plastid with a much less intense signal in the center of the plastid (Fig. 4C) .
As triclosan conjugate 7 was effective in vitro, studies were performed to determine the effect of this triclosan conjugate in vivo. For these studies, we developed a model in which tachyzoites of the RH strain were inoculated i.p. into mice. Mice were treated i.p. with r8-triclosan (conjugate ent-7) or triclosan (suspended in PBS) or PBS daily for 4 days beginning on the day they were infected. The numbers of parasites present in the peritoneal cavity were determined on the fifth day, after the 4 days of treatment. To develop and test this assay, initially, sulfadiazine was given to mice in their drinking water in the 4 days after infection. Sulfadiazine (data not shown) and r8-triclosan (conjugate ent-7), but not triclosan in PBS, reduced subsequent parasite burden (P Ͻ 0.006) (Fig. 4D) .
Our studies described herein demonstrate that short oligomers of arginine can transport inhibitory compounds into an apicomplexan parasite, including extracellular T. gondii tachyzoites and bradyzoites, intracellular tachyzoites, and encysted bradyzoites. The peptide carrier can deliver to and release lead inhibitory compounds inside tachyzoites that are multiplying within parasitophorous vacuoles, to their cytoplasm and subcellular organelles such as the apicomplexan nucleus and the perimeter of the plastid, where they are efficacious. Furthermore, octaarginine can deliver compounds into bradyzoites in cysts and tachyzoites in vivo. Oligoarginine antimicrobial conjugates provide a way to eliminate T. gondii tachyzoites and deliver antimicrobial agents to intracellular T. gondii tachyzoites and bradyzoites within cysts.
It is noteworthy that after crossing the host cell external membrane, octaarginine can cross each of the obstacles the parasite has specified to create sequestered, protected, intracellular or intracyst niches. Most notably, the carrier with its antimicrobial cargo crosses the walls of the cysts that contain untreatable bradyzoite forms of the parasite. No currently used antimicrobial compound previously has been shown to cross the cyst wall.
We selected, designed, and developed a method of delivery as a generic proof of principle, showing the ability of a carrier to deliver small molecules to microbes that are sequestered by multiple membranes and structures. This proof of principle is based on discoveries reported herein of a promising enzyme target for antimicrobials (TgENR), production and purification of recombinant TgENR, demonstration and characterization of TgENR activity, and kinetics of its inhibition by triclosan that parallels kinetics of the release of triclosan from the octaarginine carrier. Deductions concerning the structure of this promising enzyme target are then used to design an approach for testing efficacy and toxicity of releasable octaarginine inhibitor conjugates (Fig. 4) . Identification and characterization of this enzyme in T. gondii provides useful information for further development of unique classes of antimicrobial agents effective against apicomplexans. It was not obvious or certain a priori that T. gondii would have this enzyme as certain organisms, e.g., the pneumococcus, that use type II fatty acid synthesis do not have an ENR. As a proof of concept, our observations show the potential for delivery, with efficacy and without toxicity, of an inhibitor of ENR by a releasable carrier in vitro and in vivo (Figs. 3 and 4) .
We demonstrate a mechanism of medicine delivery to an important pathogen target enzyme. Octaarginine delivers a "prodrug" processed by the organism to an enzyme that is essential for pathogen survival. A number of inhibitors of ENR described so far are inherently poorly soluble in part because they reflect the lipophilic nature of the enzyme substrate. One clear advantage of the delivery system is that the specific solubilizing agent attaches a strongly hydrophilic functionality to the drug, which gives rise to freely soluble compounds.
As short oligomers of arginine are being optimized for use in delivery across skin, eye, and blood-brain barrier, results described herein provide potential for significantly improving treatment of apicomplexan, and perhaps other, infections. Future characterization of the mechanisms whereby the parasite cyst wall and multiple host and parasite membranes (of prokaryotic and eukaryotic lineage) are traversed by short arginine oligomers to deliver its antimicrobial agent cargo will be of considerable interest.
